Skip to contentHome page Seeking Alpha - Power to InvestorsStock IdeasMar 25, 2026, 3:09 PM ETTerns Pharmaceuticals, Inc. (TERN) Stock, MRK Stock, MRK:CA StockEdmund InghamInvesting Group LeaderCommentsSummaryMerck & Co., Inc. acquires Terns Pharmaceuticals, Inc. for $53/share, valuing the deal at ~$6.7bn, to secure TERN-701's blockbuster CML potential.TERN-701's Phase 1 data show a 75% MMR rate at 24 weeks, significantly outperforming current standard-of-care therapies like Novartis' Scemblix.MRK seeks to offset looming Keytruda patent expiry by adding high-potential oncology assets, with TERN-701 positioned as a future growth driver.While the acquisition introduces execution and regulatory risks, MRK's diversified pipeline and strategic M&A activity support a long-term bullish outlook.Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios.